The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Is Neisseria gonorrhoeae Initiating a Future Era of Untreatable Gonorrhea?: Detailed Characterization of the First Strain with High-Level Resistance to Ceftriaxone
Open accessAbstract
Recently, the first Neisseria gonorrhoeae strain (H041) that is highly resistant to the extended-spectrum cephalosporin (ESC) ceftriaxone, the last remaining option for empirical first-line treatment, was isolated. We performed a detailed characterization of H041, phenotypically and genetically, to confirm the finding, examine its antimicrobial resistance (AMR), and elucidate the resistance mechanisms. H041 was examined using seven species-confirmatory tests, antibiograms (30 antimicrobials), porB sequencing, N. gonorrhoeae multiantigen sequence typing (NG-MAST), multilocus sequence typing (MLST), and sequencing of ESC resistance determinants ( penA , mtrR , penB , ponA , and pilQ ). Transformation, using appropriate recipient strains, was performed to confirm the ESC resistance determinants. H041 was assigned to serovar Bpyust, MLST sequence type (ST) ST7363, and the new NG-MAST ST4220. H041 proved highly resistant to ceftriaxone (2 to 4 μg/ml, which is 4- to 8-fold higher than any previously described isolate) and all other cephalosporins, as well as most other antimicrobials tested. A new penA mosaic allele caused the ceftriaxone resistance. In conclusion, N. gonorrhoeae has now shown its ability to also develop ceftriaxone resistance. Although the biological fitness of ceftriaxone resistance in N. gonorrhoeae remains unknown, N. gonorrhoeae may soon become a true superbug, causing untreatable gonorrhea. A reduction in the global gonorrhea burden by enhanced disease control activities, combined with wider strategies for general AMR control and enhanced understanding of the mechanisms of emergence and spread of AMR, which need to be monitored globally, and public health response plans for global (and national) perspectives are important. Ultimately, the development of new drugs for efficacious gonorrhea treatment is necessary.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hagman, K. E., Spratt, B. G., Balthazar, J. T., Pan, W., Judd, R. C., & Shafer, W. M. (1995) · Microbiology · doi:10.1099/13500872-141-3-611 · Cited by 368
Tapsall, J. W., Ndowa, F., Lewis, D. A., & Unemo, M. (2009) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.09.63 · Cited by 297
Self-citationCeftriaxone-Resistant Neisseria gonorrhoeae , Japan
Ohnishi, M., Saika, T., Hoshina, S., Iwasaku, K., Nakayama, S.-I., Watanabe, H., & Kitawaki, J. (2011) · Emerging Infectious Diseases · doi:10.3201/eid1701.100397 · Cited by 236
Self-citationUnemo, M., Fasth, O., Fredlund, H., Limnios, A., & Tapsall, J. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp098 · Cited by 226
Self-citationAmeyama, S., Onodera, S., Takahata, M., Minami, S., Maki, N., Endo, K., Goto, H., Suzuki, H., & Oishi, Y. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.12.3744-3749.2002 · Cited by 222
Ito, M., Deguchi, T., Mizutani, K.-S., Yasuda, M., Yokoi, S., Ito, S.-I., Takahashi, Y., Ishihara, S., Kawamura, Y., & Ezaki, T. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.1.137-143.2005 · Cited by 205
Update on the Management of Gonorrhea in Adults in the United States
Newman, L. M., Moran, J. S., & Workowski, K. A. (2007) · Clinical Infectious Diseases · doi:10.1086/511422 · Cited by 197
Unemo, M., Golparian, D., Syversen, G., Vestrheim, D. F., & Moi, H. (2010) · Eurosurveillance · doi:10.2807/ese.15.47.19721-en · Cited by 185
Self-citationVeal, W. L., Nicholas, R. A., & Shafer, W. M. (2002) · Journal of Bacteriology · doi:10.1128/jb.184.20.5619-5624.2002 · Cited by 176
Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink?
Chisholm, S. A., Mouton, J. W., Lewis, D. A., Nichols, T., Ison, C. A., & Livermore, D. M. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq289 · Cited by 174
Cited by
Antimicrobial Resistance in Neisseria gonorrhoeae in the 21st Century: Past, Evolution, and Future
Unemo, M., & Shafer, W. M. (2014) · Clinical Microbiology Reviews · doi:10.1128/cmr.00010-14 · Cited by 1,151
Self-citationSexually transmitted infections: challenges ahead
Unemo, M., Bradshaw, C. S., Hocking, J. S., de Vries, H. J. C., Francis, S. C., Mabey, D., Marrazzo, J. M., Sonder, G. J. B., Schwebke, J. R., Hoornenborg, E., et al. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30310-9 · Cited by 751
Self-citationUnemo, M., Golparian, D., Nicholas, R., Ohnishi, M., Gallay, A., & Sednaoui, P. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05760-11 · Cited by 653
Self-citationEllington, M. J., Ekelund, O., Aarestrup, F. M., Canton, R., Doumith, M., Giske, C., Grundman, H., Hasman, H., Holden, M. T. G., Hopkins, K. L., et al. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2016.11.012 · Cited by 603
Wi, T., Lahra, M. M., Ndowa, F., Bala, M., Dillon, J.-A. R., Ramon-Pardo, P., Eremin, S. R., Bolan, G., & Unemo, M. (2017) · PLOS Medicine · doi:10.1371/journal.pmed.1002344 · Cited by 600
Self-citationUnemo, M., Seifert, H. S., Hook, E. W., Hawkes, S., Ndowa, F., & Dillon, J.-A. R. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0128-6 · Cited by 524
Self-citation2012 European guideline on the diagnosis and treatment of gonorrhoea in adults
Bignell, C., Unemo, M., The European STI Guidelines Editorial Board, Radcliffe, K., Jensen, J. S., Babayan, K., Barton, S., Cusini, M., Gomberg, M., Janier, M., et al. (2013) · International Journal of STD & AIDS · doi:10.1177/0956462412472837 · Cited by 483
Self-citationAntimicrobial resistance: a global view from the 2013 World Healthcare-Associated Infections Forum
Huttner, A., Harbarth, S., Carlet, J., Cosgrove, S., Goossens, H., Holmes, A., Jarlier, V., Voss, A., Pittet, D., & participants, F. T. W. H.-A. I. F. (2013) · Antimicrobial Resistance and Infection Control · doi:10.1186/2047-2994-2-31 · Cited by 447
Emergence of Multidrug-Resistant, Extensively Drug-Resistant and Untreatable Gonorrhea
Unemo, M., & Nicholas, R. A. (2012) · Future Microbiology · doi:10.2217/fmb.12.117 · Cited by 421
Self-citationCurrent Epidemiology and Growing Resistance of Gram-Negative Pathogens
Livermore, D. M. (2012) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2012.27.2.128 · Cited by 417
Global Fluoroquinolone Resistance Epidemiology and Implictions for Clinical Use
Dalhoff, A. (2012) · Interdisciplinary Perspectives on Infectious Diseases · doi:10.1155/2012/976273 · Cited by 354
Eyre, D. W., Sanderson, N. D., Lord, E., Regisford-Reimmer, N., Chau, K., Barker, L., Morgan, M., Newnham, R., Golparian, D., Unemo, M., et al. (2018) · Eurosurveillance · doi:10.2807/1560-7917.es.2018.23.27.1800323 · Cited by 348
Self-citationCamara, J., Serra, J., Ayats, J., Bastida, T., Carnicer-Pont, D., Andreu, A., & Ardanuy, C. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks162 · Cited by 339
Dhingra, S., Rahman, N. A. A., Peile, E., Rahman, M., Sartelli, M., Hassali, M. A., Islam, T., Islam, S., & Haque, M. (2020) · Frontiers in Public Health · doi:10.3389/fpubh.2020.535668 · Cited by 329
The growing epidemic of sexually transmitted infections in adolescents: a neglected population
Shannon, C. L., & Klausner, J. D. (2018) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000578 · Cited by 298
Unemo, M., Golparian, D., Sánchez-Busó, L., Grad, Y., Jacobsson, S., Ohnishi, M., Lahra, M. M., Limnios, A., Sikora, A. E., Wi, T., et al. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw288 · Cited by 297
Self-citationThe Emerging Threat of Untreatable Gonococcal Infection
Bolan, G. A., Sparling, P. F., & Wasserheit, J. N. (2012) · New England Journal of Medicine · doi:10.1056/nejmp1112456 · Cited by 279
Unemo, M., Lahra, M. M., Cole, M., Galarza, P., Ndowa, F., Martin, I., Dillon, J.-A. R., Ramon-Pardo, P., Bolan, G., & Wi, T. (2019) · Sexual Health · doi:10.1071/sh19023 · Cited by 262
Self-citationLahra, M. M., Martin, I., Demczuk, W., Jennison, A. V., Lee, K.-I., Nakayama, S.-I., Lefebvre, B., Longtin, J., Ward, A., Mulvey, M. R., et al. (2018) · Emerging Infectious Diseases · doi:10.3201/eid2404.171873 · Cited by 239
Self-citationKirkcaldy, R. D., Zaidi, A., Hook, E. W., Holmes, K. K., Soge, O., del Rio, C., Hall, G., Papp, J., Bolan, G., & Weinstock, H. S. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-5-201303050-00004 · Cited by 115
“Thus, it may not be a coincidence that the recently described ceftriaxone-resistant isolate from Japan was isolated from the pharynx of a female commercial sex worker (19).”
BackgroundJennison, A. V., Whiley, D., Lahra, M. M., Graham, R. M., Cole, M. J., Hughes, G., Fifer, H., Andersson, M., Edwards, A., & Eyre, D. (2019) · Eurosurveillance · doi:10.2807/1560-7917.es.2019.24.8.1900118 · Cited by 114
“Prior to the three cases reported here, no ceftriaxone resistant isolates have additionally exhibited high-level resistance to azithromycin (minimum inhibitory concentration (MIC) ≥ 256 mg/L) [3-8].”
BackgroundJean, S., Juneau, R. A., Criss, A. K., & Cornelissen, C. N. (2016) · Infection and Immunity · doi:10.1128/iai.00319-16 · Cited by 63
van der Veen, S. (2023) · Infectious Microbes and Diseases · doi:10.1097/im9.0000000000000113 · Cited by 49
Structural analysis of haemoglobin binding by HpuA from the Neisseriaceae family
Wong, C. T., Xu, Y., Gupta, A., Garnett, J. A., Matthews, S. J., & Hare, S. A. (2015) · Nature Communications · doi:10.1038/ncomms10172 · Cited by 30
Metadata
- Authors
- Ohnishi, M., Golparian, D., Shimuta, K., Saika, T., Hoshina, S., Iwasaku, K., Nakayama, S.-I., Kitawaki, J., & Unemo, M.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2011-07
- Volume
- 55
- Issue
- 7
- Pages
- 3538-3545
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W1982392457
- Cited by
- 686
- References
- 30
- FWCI
- 25.51
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.